GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...

On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the ...

Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most ...

Novo Nordisk's blockbuster Wegovy weight-loss drug beat sales expectations ... will assume responsibility for the company's commercial operation in the U.S. while staying in charge of global ...

Taiwan's China Airlines is nearing a decision to split a multi-billion-dollar order for long-distance passenger jets between ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...

The best known is semaglutide, marketed as Ozempic for diabetes, and as Wegovy for weight loss ... and reconfiguration of ...